Compare TG Therapeutics Inc (TGTX) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Unilever plc — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Unilever plc trades at $61.75 (market cap $134.06B). The key difference: Unilever plc is far larger — about 17.5× TG Therapeutics Inc's market cap, and Unilever plc pays a 3.65% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | UL | |
|---|---|---|
Market Cap | $7.64B | $134.06B |
Sector | Health | Consumer Staples |
52-Week High | $59.06 | $74.59 |
52-Week Low | $26.94 | $55.05 |
Enterprise Value | $7.84B | $159.86B |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Unilever (UL) trades at $61.75, down 1.77% with bearish technical signals. The company reported strong Q2 2026 results with 5.8% underlying sales growth - the strongest in a decade - prompting a raised full-year outlook. Despite recent earnings misses, UL maintains robust profitability with 18.75% net margins and 53.32% ROE. The pending $65 billion McCormick merger and potential Thorne acquisition signal strategic expansion.
UL presents a mixed outlook with strong fundamentals offset by recent underperformance. The merger potential offers growth catalysts, but consecutive earnings misses and bearish technicals warrant caution. Analyst consensus leans neutral (51% Hold) with balanced buy/sell ratings. Key risks include integration challenges and competitive pressures in consumer goods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
